Ironwood Pharmaceuticals

Overview

Ironwood Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts, founded in 1998. The company focuses on discovering, developing, and commercializing prescription medicines for gastrointestinal (GI) disorders. Ironwood aims to redefine the standard of care for patients with GI conditions.

The company's flagship product is LINZESS® (linaclotide), approved in 2012 for treating irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in adults. Ironwood co-develops and co-commercializes LINZESS with AbbVie Inc. Additionally, Ironwood expanded its product pipeline with the acquisition of apraglutide in 2023. The company emphasizes a focused strategy on GI and pain management, fostering strong relationships with gastroenterologists and specialists. Ironwood operates with core values centered on transforming patient lives, innovating meaningfully, and owning outcomes. The company is committed to long-term development and aims to build a sustainable pharmaceutical enterprise.

Basic Information

Contact Details

• Phone: +1 617-621-7722
• Website: ironwoodpharma.com
• LinkedIn: linkedin.com/company/ironwood-pharmaceuticals

Key Focus Areas & Initiatives

• Healthcare
• Biotechnology: pharmaceutical preparations
• Health care
• Biotechnology research
• Healthcare industry
• Short bowel syndrome
• Biotech GI pipeline
• Patient outcomes
• IBS-C
• Therapeutic pipeline
• Collaborative science
• Medical therapies
• Drug commercialization
• Drug pipeline
• Long-acting peptide analogs
• GI disease treatment
• Clinical trials
• Pharmaceuticals
• Biopharmaceutical development
• Gastrointestinal disorders
• Biotech innovation
• Biopharmaceutical pipeline
• GI health
• Specialized GI drugs
• Healthcare solutions
• Healthcare innovation
• Medical advancements
• Biotech GI research
• Rare GI diseases
• Long-acting GLP-2 analog
• Clinical research
• Clinical development
• Innovative GI therapies
• Drug development
• Global markets
• Medical science
• Biotech
• Gastroenterology
• Biotech company
• Unmet medical needs
• Prescription drugs
• Biopharma
• Rare disease therapies
• Gastroenterology innovation
• GLP-2 analog
• Rare diseases
• Biotechnology
• Prescription medications
• Biotech for GI health
• Biotech therapies
• Biotech research
• Biotech pipeline
• Innovative therapies
• Sustainable growth
• LINZESS
• Gastrointestinal diseases
• B2B
• Sustainability
• Biotech drug development
• Medical research
• Patient care
• Gastrointestinal health
• Parenteral support
• CIC
• Drug discovery
• Medical treatments
• Medical innovation
• Pharmaceutical and medicine manufacturing
• Apraglutide
• Patient-centric
• Biotech research in GI
• Biopharmaceutical
• Clinical-stage therapies
• Acquisitions
• Patient-focused R&D
• Gastrointestinal
• GI healthcare
• GI diseases
• Linaclotide
• Irritable bowel syndrome
• Chronic idiopathic constipation
• Functional constipation
• Pediatric treatment
• Intestinal failure
• Unmet needs
• Therapeutic focus
• Pipeline
• Care standards
• Research and development
• Healthcare costs
• Patient journey
• Chronic GI conditions
• Scientific advancements
• Disease management
• Quality of life improvement
• Pharmaceutical development
• Collaboration
• Clinical efficacy
• Patient-centered care
• Therapeutic innovation
• Symptom relief
• Healthcare access
• Market leader
• Health management
• Pharmacotherapy
• Patient support
• Healthcare research
• Community engagement
• Manufacturing
• Health, wellness & fitness
• Hospital & health care
• Medical
• Environmental services
• Renewables & environment
• Research & development
• Mechanical or industrial engineering

Technologies Used

• Amazon SES
• Drupal
• EasyDNS
• Google Analytics
• Google Font API
• Google Tag Manager
• IoT
• Microsoft Office 365
• Microsoft PowerPoint
• Mimecast
• Mobile Friendly
• Outlook
• Rackspace MailGun
• React
• Remote
• Slack
• WP Engine
• WordPress.org
• reCAPTCHA

Affiliated Organizations & Regional Branches

• VectivBio AG